|
Monday, April 12, 2010
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
3G Bio Tech, LLC
Biotech Medical Company
About
|
Zinc Removal Prevents Biofilm Formation
3G targets the $45 billion Hospital-Acquired Infection (HAIs) Market and the $20 billion Chronic Wound Care Market by preventing biofilm formation. Biofilm formation is a major barrier to wound healing, with 80% of microbial infections involving biofilm. By removing zinc, Staphylococcal species, including S. aureus (MRSA) and S. epidermidis, are unable to form biofilm.
In collaboration with the University of Cincinnati, 3G has obtained exclusive, worldwide distribution rights to Zinc Chelation Technology.
HAIs have become more common and more deadly over the last few years for three primary reasons:
- Hospital Dynamics - Healthcare staff are now spread over a larger patient base, creating more opportunities for pathogens to be transmitted
- Antibiotic Over-Prescribing - Over the last 20-30 years, antibiotics have become increasingly prescribed for all sorts of common illnesses where they are of questionable benefit
- Ineffective Infection Control Programs - There is little evidence that the programs being implemented are effective. The Leapfrog Group reports, “87% of US hospitals do not take recommended steps to prevent avoidable infections”
Only now is biofilm being recognized as an integral part in preventing and treating infections.
3 Major Issues
|
- Will 505 (b)(2) be the correct regulatory pathway for combining two already FDA approved products? And avoid the 510K process.
- We are not planning to be involved in a Randomized Controlled Trial since our products are already FDA approved. Will this hurt us?
- Can we include reimbursement for our products into an already existing reimbursement group? Such as diabetic wound care, decubitis ulcers, etc.?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Gary Young, President and CEO of 3G Bio Tech will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
Contact Info:
Gary Young, PharmD, RPh, MBA, USMC
President/CEO/Founder
3G BioTech, LLC
TEL: (978) 505-5277
|
|
|
Slides
Audio
Video
Webcast
